A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: CREXONT ER
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06765668
- Locations
- 🇺🇸
N1 Research LLC, Orlando, Florida, United States
🇺🇸Parkinson's Research Centers of America - Long Island, Commack, New York, United States
🇺🇸MedStar Georgetown University Hospital Department of Neurology, McLean, Virginia, United States
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT06161220
- Locations
- 🇺🇸
AXIS Clinicals, LLC, Dilworth, Minnesota, United States
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT03877510
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center (123), Cleveland, Ohio, United States
🇺🇸Neurology Consultants of Dallas, PA (108), Dallas, Texas, United States
🇺🇸Northwestern Medical Group Neurology Clinic (145), Chicago, Illinois, United States
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- Drug: IPX203 ER CD-LDDrug: IR CD-LDOther: Placebo Matching IR CD-LDOther: Placebo Matching IPX203
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 630
- Registration Number
- NCT03670953
- Locations
- 🇺🇸
University of Miami-UHealth at Boca Raton (152), Boca Raton, Florida, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton (121), Boca Raton, Florida, United States
🇺🇸Keck School of Medicine of USC/University of Southern California (106), Los Angeles, California, United States
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
- Conditions
- Migraine
- Interventions
- Drug: Placebo ZNSDrug: ZNS
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 374
- Registration Number
- NCT03275922
- Locations
- 🇺🇸
Clinical Integrative Research Center of Atlanta (121), Atlanta, Georgia, United States
🇺🇸iResearch Atlanta, LLC (146), Decatur, Georgia, United States
🇺🇸Akron Children's Hospital (site 139), Akron, Ohio, United States
A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03007888
- Locations
- 🇺🇸
Site 114, Little Rock, Arkansas, United States
🇺🇸Investigator 109, Cleveland, Ohio, United States
🇺🇸Investigator 104, Spokane, Washington, United States
A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02271503
- Locations
- 🇺🇸
Muhammad Ali Movement Disorder Center (MAMDC), Phoenix, Arizona, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸QUEST Research Institute, Farmington Hills, Michigan, United States
Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 159
- Registration Number
- NCT01521663
- Locations
- 🇺🇸
University of Alabama at Birmingham, Brimingham, Alabama, United States
🇺🇸Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸Scripps Clinic, La Jolla, California, United States
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01411137
- Locations
- 🇺🇸
The Parkinson's Institute, Sunnyvale, California, United States
🇺🇸University of Nevada School of Medicine, Las Vegas, Nevada, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Long Island, Commack, New York, United States
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT01130493
- Locations
- 🇺🇸
Margolin Brain Institute, Fresno, California, United States
🇺🇸Charlotte Neurological Services, Port Charlotte, Florida, United States
🇺🇸UM Movement Disorders Center, Miami, Florida, United States